Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Optimizing Hydroxyurea Therapy for Sickle Cell Anemia
source: Hematology / The Education Program of the American Society of Hematology
year: 2015
authors: Russell E. Ware
summary/abstract:Hydroxyurea has proven efficacy in numerous clinical trials as a disease-modifying treatment for patients with sickle cell anemia (SCA) but is currently under-used in clinical practice. To improve the effectiveness of hydroxyurea therapy, efforts should be directed toward broadening the clinical treatment indications, optimizing the daily dosage, and emphasizing the benefits of early and extended treatment. Here, various issues related to hydroxyurea treatment are discussed, focusing on both published evidence and clinical experience. Specific guidance is provided regarding important but potentially unfamiliar aspects of hydroxyurea treatment for SCA, such as escalating to maximum tolerated dose, treating in the setting of cerebrovascular disease, switching from chronic transfusions to hydroxyurea, and using serial phlebotomy to alleviate iron overload.
Future research directions to optimize hydroxyurea therapy are also discussed, including personalized dosing based on pharmacokinetic modeling, prediction of fetal hemoglobin responses based on pharmacogenomics, and the risks and benefits of hydroxyurea for non-SCA genotypes and during pregnancy/lactation. Another critical initiative is the introduction of hydroxyurea safely and effectively into global regions that have a high disease burden of SCA but limited resources, such as sub-Saharan Africa, the Caribbean, and India. Final considerations emphasize the long-term goal of optimizing hydroxyurea therapy, which is to help treatment become accepted as standard of care for all patients with SCA.
organization: Cincinnati Children's Hospital Medical Center, USADOI: 10.1182/asheducation-2015.1.436
read more full text
+myBinderRelated Content
-
Hydroxyurea linked to ‘significant, rapid’ reduction of sperm countSix months of hydroxyurea therapy detrim...
-
Hydroxycarbamide for Children With Sickle Cell Disease (SCD)Hydroxycarbamide is a medicine taken by ...
-
A Conversation on Hydroxyurea: Insights and Information for the Sickle Cell Communityhttps://www.youtube.com/watch?v=Y6fmJn-5...
-
Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: A British society for ha...Sickle cell disease (SCD) is a generic t...
-
Sickle Cell Disease Research Shows Progress in Preventing Related Complications and DeathStudies aim to limit pain crises, preven...
-
Discovery could help treatments for sickle cell diseaseResearch team establishes biomarkers for...
-
Developing Hydroxyurea, the First FDA-Approved Therapy for Sickle Cell Diseasehttps://www.youtube.com/watch?v=0kIz5ZKy...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.